Travere officer plans $7.1M stock sale

Officer William Rote files to sell 112,850 TVTX shares following a stock option exercise, with prior 10b5-1 sales also disclosed.

Rhea-AI Filing Summary

Travere Therapeutics, Inc. (TVTX) is the issuer in a notice that officer William Rote intends to sell 112,850 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $7,054,253.50, as of a proposed sale date of September 16, 2026 on NASDAQ.

The shares to be sold were acquired from the issuer on September 16, 2026 via an exercise of stock options paid in cash. The notice also reports that during the prior three months, a separate Rule 10b5-1 sales program for E. Rote involved the sale of 96,198 shares of common stock on September 15, 2026 for aggregate proceeds of $5,988,758.39.

Key Figures

Shares to be sold: 112,850 shares Aggregate market value of proposed sale: $7,054,253.50 Shares outstanding: 94,261,082 shares +4 more

7 metrics

Shares to be sold 112,850 shares Common stock proposed for sale by officer William Rote under Rule 144

Aggregate market value of proposed sale $7,054,253.50 Market value of 112,850 shares of common stock related to the planned Rule 144 sale

Shares outstanding 94,261,082 shares Common stock of Travere Therapeutics outstanding referenced in the notice

Shares sold in past 3 months 96,198 shares Common shares sold on September 15, 2026 under a Rule 10b5-1 sales program for E. Rote

Aggregate proceeds from past 3-month sales $5,988,758.39 Aggregate proceeds from 96,198 common shares sold on September 15, 2026

Proposed sale date September 16, 2026 Date associated with the proposed Rule 144 sale of 112,850 shares

Date of prior 10b5-1 sale September 15, 2026 Date of the 96,198-share sale under a Rule 10b5-1 sales program

Key Terms

Rule 144, 10b5-1, Exercise of Stock Options, aggregate market value

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for E ROTE 3611 Valley Centre Drive, Suite 300"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

Exercise of Stock Options financial

"Common | 09/16/2026 | Exercise of Stock Options | Issuer"

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Travere Therapeutics (TVTX)?

The filing discloses that officer William Rote intends to sell 112,850 shares of Travere Therapeutics common stock, with an aggregate market value of $7,054,253.50, through Morgan Stanley Smith Barney LLC on or about September 16, 2026 under Rule 144.

How many Travere Therapeutics (TVTX) shares has the filer sold recently?

The notice reports that, in the past three months, a Rule 10b5-1 sales program for E. Rote involved the sale of 96,198 shares of Travere Therapeutics common stock on September 15, 2026 for aggregate proceeds of $5,988,758.39.

How are the shares in the Travere Therapeutics (TVTX) Form 144 being acquired?

The 112,850 shares covered by the Form 144 are being acquired from Travere Therapeutics via an exercise of stock options on September 16, 2026, with the nature of payment identified as cash before the intended resale under Rule 144.

Which broker is handling the planned sale of TVTX shares under this Form 144?

The planned sale of 112,850 shares of Travere Therapeutics common stock is listed as being handled by Morgan Stanley Smith Barney LLC Executive Financial Services, located at 1 New York Plaza, New York, with trading on NASDAQ as disclosed.

What is the total number of Travere Therapeutics (TVTX) shares outstanding mentioned?

The filing notes that Travere Therapeutics has 94,261,082 shares of common stock outstanding in connection with the Rule 144 notice, providing context for the 112,850 shares proposed to be sold by officer William Rote.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 04:34 PM Accepted by SEC EDGAR 09/16/2026 - 04:33 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001698262
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TRAVERE THERAPEUTICS INC
SEC File Number	001-36257
Address of Issuer	3611 Valley Centre Drive, Suite 300 San Diego CALIFORNIA 92130
Phone	8889697879
Name of Person for Whose Account the Securities are To Be Sold	WILLIAM ROTE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	112850	7054253.50	94261082	09/16/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/16/2026	Exercise of Stock Options	Issuer			112850	09/16/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for WILLIAM E ROTE 3611 Valley Centre Drive, Suite 300 San Diego CA 92130	Common	09/15/2026	96198	5988758.39

144: Remarks and Signature

Remarks
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ William Rote
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)